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Objectives: The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous
administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current
standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use of sub-
cutaneous sarilumab in early stages (window of opportunity) of COVID-19 moderate-severe pneumonia can prevent
higher oxygenation requirements through non-invasive and invasive mechanical ventilation and decrease in-
hospital stays, as well as death rate.
The secondary objectives of the study are to evaluate the safety of sarilumab through hospitalisation and up to day
14 after discharge, compared to the control arm as assessed by incidence of serious and non serious adverse
events (SAEs).
In addition, as an exploratory objective, to compare the baseline clinical and biological parameters, including serum
IL-6 levels, of the intervention population against controls of the same pandemic outbreak (using a propensity
score) to search for markers that identify the best candidates for the treatment with subcutaneous IL-6R inhibitors
and to attempt an approximation in the temporal frame of the “window of opportunity”
Trial design: SARCOVID is an investigator-initiated single center randomised proof of concept study.
Participants: Patients treated at the Hospital Universitario La Princesa, Madrid, Spain requiring hospitalisation will
be consecutively recruited, meeting all inclusion criteria and none of the exclusion criteria
Inclusion criteria
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a. Age >18, <80 years old
b. COVID-19 infection documented by a positive RT-PCR test or, in absence of a RT-PCR positive test, case definition
of COVID 19 infection/pneumonia as per local protocol and the presence of a positive serologic test (IgM/IgA by
ELISA)
c. Documented interstitial pneumonia requiring admission and at least two of the following parameters:
1) Fever ≥ 37.8°C (tympanic)
2) IL-6 in serum ≥ 25 pg/mL (in the absence of a previous dose of prednisone or equivalent> 1 mg / kg) or PCR>
5mg/dL
3) Lymphocytes <600 cells/mm3
4) Ferritin> 300 μg/L that doubles in 24 hours
5) Ferritin> 600 μg/L in the first determination and LDH> 250 U/L
6) D-dimer (> 1 mg/L)
d. Informed verbal consent or requested under urgent conditions, documented in the electronic medical record.
Exclusion criteria
a. Patients who require mechanical ventilation at the time of inclusion.
b. AST / ALT values > 5 folds the ULN.
c. Absolute neutrophil count below 500 cells/mm3
d. Absolute platelet count below 50,000 cells/mm3
e. Documented sepsis or high suspicion of superimposed infection by pathogens other than COVID-19.
f. Presence of comorbidities that can likely lead to an unfavourable result according to clinical judgment.
g. Complicated diverticulitis or intestinal perforation.
h. Current skin infection (eg, uncontrolled dermopiodermitis).
i. Immunosuppressive anti-rejection therapy.
j. Pregnancy or lactation.
k. Previous treatment with tocilizumab or sarilumab.
l. Patients participating in another clinical trial for SARS-CoV-2 infection.
m. Patients with known hypersensitivity or contraindication to sarilumab or excipients.
Intervention and comparator: The intervention group, sarilumab plus standard of care, will receive 400 mg single
dose treatment with Sarilumab (Kevzara), 2 subcutaneous injections 200mg each in a pre-filled syringe. Treatment
with drugs or procedures in routine clinical practice that the clinician responsible for the patient deems necessary is
allowed.
The control group will receive drugs or procedures in routine clinical practice according to the best standard of
care as per local protocol.
Main outcomes: Primary Outcome Measures
1. Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation compared
to baseline (Score ranges 1-7)
1. Death;
2. Hospitalised, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);
3. Hospitalised, requiring non-invasive ventilation or high flow oxygen devices;
4. Hospitalised, requiring supplemental oxygen;
5. Hospitalised, not requiring supplemental oxygen - but in need of ongoing medical care (COVID-19 related or
otherwise)
6. Hospitalised, not requiring supplemental oxygen - no longer requires ongoing medical care (independent)
7. Not hospitalised
2. Duration of hospitalisation: Days from the date of enrolment to the date of discharge
3. Number of deaths at the end of study
(Continued on next page)
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Randomisation: Randomisation to treatment arms sarilumab plus standard of care or standard of care in a 2:1 ratio
will be performed by the Clinical Research and Clinical Trials Unit (CRCTU) at the Hospital using a table of random
numbers, an internet-based randomisation tool. After checking that all inclusion criteria are met and none of the
exclusion criteria, CRCTU will communicate the recruiting investigator the assigned treatment.
Blinding (masking): This study is unblinded.
Numbers to be randomised (sample size): 30 patients treated by COVID-19 infection who require hospitalisation:
20 will receive sarilumab plus Standard of Care and 10 will receive Standard of Care.
Trial Status: The Protocol version number is 2, as of 6th April 2020, with amendment 1, as of 7th May 2020. The
recruitment is ongoing. Recruitment started on April 13th 2020 and is anticipated to be completed by November
2020.
Trial registration: This trial was first registered in the European Union Clinical Trials Register on 4 April 2020,
EudraCT Number 2020-001634-36. Then, posted on ClinicalTrials.gov on 22 April 2020, Identifier: NCT04357808.
Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1).
In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter
serves as a summary of the key elements of the full protocol.
The study protocol has been reported in accordance with the International Council Harmonization guidelines:
https://www.ich.org/page/efficacy-guidelines.
Keywords: COVID-19, Randomised controlled trial, Open label trial, protocol, SARS-CoV-2, Coronavirus infections,
Sarilumab, IL-6 receptor inhibitorsSupplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04588-5.
Additional file 1. Full Study Protocol.
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